Wyeth, Karo Bio Stop Development Of LXR-623 For Atherosclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Another Liver X Receptor development duo, Exelixis and Bristol-Myers Squibb, extend their cardiovascular and metabolic drug development pact through January 2009.